Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 179

1.

Broadly inhibiting anti-neuraminidase monoclonal antibodies induced by trivalent influenza vaccine and H7N9 infection in humans.

Rijal P, Wang BB, Tan TK, Schimanski L, Janesch P, Dong T, McCauley JW, Daniels RS, Townsend AR, Huang KA.

J Virol. 2019 Nov 20. pii: JVI.01182-19. doi: 10.1128/JVI.01182-19. [Epub ahead of print]

2.

Detection of Influenza C Virus Infection among Hospitalized Patients, Cameroon.

Njouom R, Monamele GC, Ermetal B, Tchatchouang S, Moyo-Tetang S, McCauley JW, Daniels RS.

Emerg Infect Dis. 2019 Mar;25(3):607-609. doi: 10.3201/eid2503.181213.

3.

A single cycle influenza virus coated in H7 haemagglutinin generates neutralizing antibody responses to haemagglutinin and neuraminidase glycoproteins and protection from heterotypic challenge.

Powell TJ, Rijal P, McEwen-Smith RM, Byun H, Hardwick M, Schimanski LM, Huang KA, Daniels RS, Townsend ARM.

J Gen Virol. 2019 Mar;100(3):431-445. doi: 10.1099/jgv.0.001228. Epub 2019 Feb 4.

PMID:
30714896
4.

Association of Increased Receptor-Binding Avidity of Influenza A(H9N2) Viruses with Escape from Antibody-Based Immunity and Enhanced Zoonotic Potential.

Sealy JE, Yaqub T, Peacock TP, Chang P, Ermetal B, Clements A, Sadeyen JR, Mehboob A, Shelton H, Bryant JE, Daniels RS, McCauley JW, Iqbal M.

Emerg Infect Dis. 2018 Jan;25(1):63-72. doi: 10.3201/eid2501.180616.

5.

Overview of three influenza seasons in Georgia, 2014-2017.

Machablishvili A, Chakhunashvili G, Zakhashvili K, Karseladze I, Tarkhan-Mouravi O, Gavashelidze M, Jashiashvili T, Sabadze L, Imnadze P, Daniels RS, Ermetal B, McCauley JW.

PLoS One. 2018 Jul 27;13(7):e0201207. doi: 10.1371/journal.pone.0201207. eCollection 2018.

6.

Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016-2017.

Lackenby A, Besselaar TG, Daniels RS, Fry A, Gregory V, Gubareva LV, Huang W, Hurt AC, Leang SK, Lee RTC, Lo J, Lollis L, Maurer-Stroh S, Odagiri T, Pereyaslov D, Takashita E, Wang D, Zhang W, Meijer A.

Antiviral Res. 2018 Sep;157:38-46. doi: 10.1016/j.antiviral.2018.07.001. Epub 2018 Jul 3.

7.

Characterization of neutralizing epitopes in antigenic site B of recently circulating influenza A(H3N2) viruses.

Beer K, Dai M, Howell S, Rijal P, Townsend AR, Lin Y, Wharton SA, Daniels RS, McCauley JW.

J Gen Virol. 2018 Aug;99(8):1001-1011. doi: 10.1099/jgv.0.001101. Epub 2018 Jun 26.

8.

Genome-wide evolutionary dynamics of influenza B viruses on a global scale.

Langat P, Raghwani J, Dudas G, Bowden TA, Edwards S, Gall A, Bedford T, Rambaut A, Daniels RS, Russell CA, Pybus OG, McCauley J, Kellam P, Watson SJ.

PLoS Pathog. 2017 Dec 28;13(12):e1006749. doi: 10.1371/journal.ppat.1006749. eCollection 2017 Dec.

9.

Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016.

Gubareva LV, Besselaar TG, Daniels RS, Fry A, Gregory V, Huang W, Hurt AC, Jorquera PA, Lackenby A, Leang SK, Lo J, Pereyaslov D, Rebelo-de-Andrade H, Siqueira MM, Takashita E, Odagiri T, Wang D, Zhang W, Meijer A.

Antiviral Res. 2017 Oct;146:12-20. doi: 10.1016/j.antiviral.2017.08.004. Epub 2017 Aug 10.

10.

The characteristics and antigenic properties of recently emerged subclade 3C.3a and 3C.2a human influenza A(H3N2) viruses passaged in MDCK cells.

Lin Y, Wharton SA, Whittaker L, Dai M, Ermetal B, Lo J, Pontoriero A, Baumeister E, Daniels RS, McCauley JW.

Influenza Other Respir Viruses. 2017 May;11(3):263-274. doi: 10.1111/irv.12447. Epub 2017 Feb 28.

11.

Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014-2015.

Hurt AC, Besselaar TG, Daniels RS, Ermetal B, Fry A, Gubareva L, Huang W, Lackenby A, Lee RT, Lo J, Maurer-Stroh S, Nguyen HT, Pereyaslov D, Rebelo-de-Andrade H, Siqueira MM, Takashita E, Tashiro M, Tilmanis D, Wang D, Zhang W, Meijer A.

Antiviral Res. 2016 Aug;132:178-85. doi: 10.1016/j.antiviral.2016.06.001. Epub 2016 Jun 3. Review.

12.

Antigenic characterization of influenza viruses produced using synthetic DNA and novel backbones.

Suphaphiphat P, Whittaker L, De Souza I, Daniels RS, Dormitzer PR, McCauley JW, Settembre EC.

Vaccine. 2016 Jul 12;34(32):3641-8. doi: 10.1016/j.vaccine.2016.05.031. Epub 2016 May 21.

13.

Identification of Low- and High-Impact Hemagglutinin Amino Acid Substitutions That Drive Antigenic Drift of Influenza A(H1N1) Viruses.

Harvey WT, Benton DJ, Gregory V, Hall JP, Daniels RS, Bedford T, Haydon DT, Hay AJ, McCauley JW, Reeve R.

PLoS Pathog. 2016 Apr 8;12(4):e1005526. doi: 10.1371/journal.ppat.1005526. eCollection 2016 Apr.

14.

Effects of egg-adaptation on receptor-binding and antigenic properties of recent influenza A (H3N2) vaccine viruses.

Parker L, Wharton SA, Martin SR, Cross K, Lin Y, Liu Y, Feizi T, Daniels RS, McCauley JW.

J Gen Virol. 2016 Jun;97(6):1333-1344. doi: 10.1099/jgv.0.000457. Epub 2016 Mar 14.

15.

Prediction, dynamics, and visualization of antigenic phenotypes of seasonal influenza viruses.

Neher RA, Bedford T, Daniels RS, Russell CA, Shraiman BI.

Proc Natl Acad Sci U S A. 2016 Mar 22;113(12):E1701-9. doi: 10.1073/pnas.1525578113. Epub 2016 Mar 7.

16.

Improving the representativeness of influenza viruses shared within the WHO Global Influenza Surveillance and Response System.

Pereyaslov D, Zemtsova G, Gruessner C, Daniels RS, McCauley JW, Brown CS.

Influenza Other Respir Viruses. 2016 Mar;10(2):68-75. doi: 10.1111/irv.12362.

17.

Influenza virus surveillance in Argentina during the 2012 season: antigenic characterization, genetic analysis and antiviral susceptibility.

Benedetti E, Daniels RS, Pontoriero A, Russo M, Avaro M, Czech A, Campos A, Periolo N, Gregory V, McCauley JW, Baumeister EG.

Epidemiol Infect. 2016 Mar;144(4):751-67. doi: 10.1017/S0950268815001806. Epub 2015 Sep 8.

18.

Optimisation of a micro-neutralisation assay and its application in antigenic characterisation of influenza viruses.

Lin Y, Gu Y, Wharton SA, Whittaker L, Gregory V, Li X, Metin S, Cattle N, Daniels RS, Hay AJ, McCauley JW.

Influenza Other Respir Viruses. 2015 Nov;9(6):331-340. doi: 10.1111/irv.12333.

19.

Global circulation patterns of seasonal influenza viruses vary with antigenic drift.

Bedford T, Riley S, Barr IG, Broor S, Chadha M, Cox NJ, Daniels RS, Gunasekaran CP, Hurt AC, Kelso A, Klimov A, Lewis NS, Li X, McCauley JW, Odagiri T, Potdar V, Rambaut A, Shu Y, Skepner E, Smith DJ, Suchard MA, Tashiro M, Wang D, Xu X, Lemey P, Russell CA.

Nature. 2015 Jul 9;523(7559):217-20. doi: 10.1038/nature14460. Epub 2015 Jun 8.

20.

Focused antibody response to influenza linked to antigenic drift.

Huang KY, Rijal P, Schimanski L, Powell TJ, Lin TY, McCauley JW, Daniels RS, Townsend AR.

J Clin Invest. 2015 Jul 1;125(7):2631-45. doi: 10.1172/JCI81104. Epub 2015 May 26.

21.

Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014.

Takashita E, Meijer A, Lackenby A, Gubareva L, Rebelo-de-Andrade H, Besselaar T, Fry A, Gregory V, Leang SK, Huang W, Lo J, Pereyaslov D, Siqueira MM, Wang D, Mak GC, Zhang W, Daniels RS, Hurt AC, Tashiro M.

Antiviral Res. 2015 May;117:27-38. doi: 10.1016/j.antiviral.2015.02.003. Epub 2015 Feb 23.

22.

Influenza gain-of-function experiments: their role in vaccine virus recommendation and pandemic preparedness.

Schultz-Cherry S, Webby RJ, Webster RG, Kelso A, Barr IG, McCauley JW, Daniels RS, Wang D, Shu Y, Nobusawa E, Itamura S, Tashiro M, Harada Y, Watanabe S, Odagiri T, Ye Z, Grohmann G, Harvey R, Engelhardt O, Smith D, Hamilton K, Claes F, Dauphin G.

MBio. 2014 Dec 12;5(6). pii: e02430-14. doi: 10.1128/mBio.02430-14.

23.

Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012-2013.

Meijer A, Rebelo-de-Andrade H, Correia V, Besselaar T, Drager-Dayal R, Fry A, Gregory V, Gubareva L, Kageyama T, Lackenby A, Lo J, Odagiri T, Pereyaslov D, Siqueira MM, Takashita E, Tashiro M, Wang D, Wong S, Zhang W, Daniels RS, Hurt AC.

Antiviral Res. 2014 Oct;110:31-41. doi: 10.1016/j.antiviral.2014.07.001. Epub 2014 Jul 17.

24.

A novel I221L substitution in neuraminidase confers high-level resistance to oseltamivir in influenza B viruses.

Escuret V, Collins PJ, Casalegno JS, Vachieri SG, Cattle N, Ferraris O, Sabatier M, Frobert E, Caro V, Skehel JJ, Gamblin S, Valla F, Valette M, Ottmann M, McCauley JW, Daniels RS, Lina B.

J Infect Dis. 2014 Oct 15;210(8):1260-9. doi: 10.1093/infdis/jiu244. Epub 2014 May 3.

25.

WHO recommendations for the viruses used in the 2013-2014 Northern Hemisphere influenza vaccine: Epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from October 2012 to January 2013.

Barr IG, Russell C, Besselaar TG, Cox NJ, Daniels RS, Donis R, Engelhardt OG, Grohmann G, Itamura S, Kelso A, McCauley J, Odagiri T, Schultz-Cherry S, Shu Y, Smith D, Tashiro M, Wang D, Webby R, Xu X, Ye Z, Zhang W; Writing Committee of the World Health Organization Consultation on Northern Hemisphere Influenza Vaccine Composition for 2013–2014.

Vaccine. 2014 Aug 20;32(37):4713-25. doi: 10.1016/j.vaccine.2014.02.014. Epub 2014 Feb 28.

26.
27.

Receptor binding by an H7N9 influenza virus from humans.

Xiong X, Martin SR, Haire LF, Wharton SA, Daniels RS, Bennett MS, McCauley JW, Collins PJ, Walker PA, Skehel JJ, Gamblin SJ.

Nature. 2013 Jul 25;499(7459):496-9. doi: 10.1038/nature12372.

PMID:
23787694
28.

Evolution of the receptor binding properties of the influenza A(H3N2) hemagglutinin.

Lin YP, Xiong X, Wharton SA, Martin SR, Coombs PJ, Vachieri SG, Christodoulou E, Walker PA, Liu J, Skehel JJ, Gamblin SJ, Hay AJ, Daniels RS, McCauley JW.

Proc Natl Acad Sci U S A. 2012 Dec 26;109(52):21474-9. doi: 10.1073/pnas.1218841110. Epub 2012 Dec 10. Erratum in: Proc Natl Acad Sci U S A. 2013 Feb 12;110(7):2677.

29.

Virulence determinants of pandemic A(H1N1)2009 influenza virus in a mouse model.

Uraki R, Kiso M, Shinya K, Goto H, Takano R, Iwatsuki-Horimoto K, Takahashi K, Daniels RS, Hungnes O, Watanabe T, Kawaoka Y.

J Virol. 2013 Feb;87(4):2226-33. doi: 10.1128/JVI.01565-12. Epub 2012 Dec 5.

30.

Evaluation of influenza virus antiviral susceptibility testing in Europe: results from the first external quality assessment exercise.

Thompson CI, Lackenby A, Daniels RS, McCauley JW, Pereyaslov D, Broberg EK, Meijer A, Zambon MC.

J Clin Virol. 2013 Mar;56(3):212-8. doi: 10.1016/j.jcv.2012.11.005. Epub 2012 Nov 30.

PMID:
23201459
31.

Oseltamivir-resistant influenza A(H1N1)pdm09 virus in Dutch travellers returning from Spain, August 2012.

Meijer A, Jonges M, van Beek P, Swaan CM, Osterhaus AD, Daniels RS, Hurt AC, Koopmans MP.

Euro Surveill. 2012 Sep 6;17(36):20266.

32.

Structural basis for oseltamivir resistance of influenza viruses.

Collins PJ, Haire LF, Lin YP, Liu J, Russell RJ, Walker PA, Martin SR, Daniels RS, Gregory V, Skehel JJ, Gamblin SJ, Hay AJ.

Vaccine. 2009 Oct 23;27(45):6317-23. doi: 10.1016/j.vaccine.2009.07.017.

PMID:
19840667
33.

CD4 binding affinity determines human immunodeficiency virus type 1-induced alpha interferon production in plasmacytoid dendritic cells.

Haupt S, Donhauser N, Chaipan C, Schuster P, Puffer B, Daniels RS, Greenough TC, Kirchhoff F, Schmidt B.

J Virol. 2008 Sep;82(17):8900-5. doi: 10.1128/JVI.00196-08. Epub 2008 Jun 25.

35.

Functional and antigenic analyses of the 1918 influenza virus haemagglutinin using a recombinant vaccinia virus expression system.

Elliot AJ, Steinhauer DA, Daniels RS, Oxford JS.

Virus Res. 2006 Dec;122(1-2):11-9. Epub 2006 Aug 9.

PMID:
16904219
36.
37.
38.
39.

Analysis of full-length HIV type 1 env genes indicates differences between the virus infecting T cells and dendritic cells in peripheral blood of infected patients.

Daniels RS, Wilson P, Patel D, Longhurst H, Patterson S.

AIDS Res Hum Retroviruses. 2004 Apr;20(4):409-13.

PMID:
15157359
40.

The structure and receptor binding properties of the 1918 influenza hemagglutinin.

Gamblin SJ, Haire LF, Russell RJ, Stevens DJ, Xiao B, Ha Y, Vasisht N, Steinhauer DA, Daniels RS, Elliot A, Wiley DC, Skehel JJ.

Science. 2004 Mar 19;303(5665):1838-42. Epub 2004 Feb 5.

41.

1918 influenza pandemic caused by highly conserved viruses with two receptor-binding variants.

Reid AH, Janczewski TA, Lourens RM, Elliot AJ, Daniels RS, Berry CL, Oxford JS, Taubenberger JK.

Emerg Infect Dis. 2003 Oct;9(10):1249-53. No abstract available.

42.

An HIV type 1 subtype B founder effect in Korea: gp160 signature patterns infer circulation of CTL-escape strains at the population level.

Daniels RS, Kang C, Patel D, Xiang Z, Douglas NW, Zheng NN, Cho HW, Lee JS.

AIDS Res Hum Retroviruses. 2003 Aug;19(8):631-41.

PMID:
13678464
43.

CD8+ T-cell-mediated non-cytolytic suppression of human immuno-deficiency viruses.

Vella C, Daniels RS.

Curr Drug Targets Infect Disord. 2003 Jun;3(2):97-113. Review.

PMID:
12769788
44.
45.

Herpesvirus saimiri-immortalized human lymphocytes: novel hosts for analyzing HIV type 1 in vitro neutralization.

Vella C, Zheng NN, Easterbrook P, Daniels RS.

AIDS Res Hum Retroviruses. 2002 Sep 1;18(13):933-46.

PMID:
12230936
46.
47.

World War I may have allowed the emergence of "Spanish" influenza.

Oxford JS, Sefton A, Jackson R, Innes W, Daniels RS, Johnson NP.

Lancet Infect Dis. 2002 Feb;2(2):111-4.

PMID:
11901642
48.

Construction and characterization of a full-length HIV-1(92UG001) subtype D infectious molecular clone.

Novelli P, Vella C, Oxford J, Daniels RS.

AIDS Res Hum Retroviruses. 2002 Jan 1;18(1):85-8.

PMID:
11804560
49.

Maintenance of glycoprotein-determined phenotype in an HIV type 1 (pNL43) env gene-cassetting system.

Zheng NN, Daniels RS.

AIDS Res Hum Retroviruses. 2001 Nov 1;17(16):1501-6.

PMID:
11709094
50.

Antiretroviral therapy for HIV-2 infected patients.

Smith NA, Shaw T, Berry N, Vella C, Okorafor L, Taylor D, Ainsworth J, Choudhury A, Daniels RS, El-Gadi S, Fakoya A, Moyle G, Oxford J, Tedder R, O'Shea S, de Ruiter A, Breuer J.

J Infect. 2001 Feb;42(2):126-33.

PMID:
11531319

Supplemental Content

Loading ...
Support Center